Results 131 to 140 of about 7,354 (172)

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor

Seth A. Reasoner, Rachel Bernard, Adam Waalkes, Kelsi Penewit, Janessa D. Lewis, Andrew G. Sokolow, Rebekah F. Brown, Kathryn M. Edwards, Stephen J. Salipante, Maria Hadjifrangiskou, Maribeth R. Nicholson   +10 more
openalex   +1 more source

Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden [PDF]

Anders Lindblad, Isabelle de Monestrol, Marita Gilljam, Christina Krantz, Lisa J. McGarry, Jonas Banefelt, Martina Aldvén   +6 more
openalex   +1 more source

Cystic Fibrosis: Huge Gains, but Still a Work in Progress. [PDF]

Am J Respir Crit Care Med
Bush A, Ramsey BW.
europepmc   +1 more source

Implications for cystic fibrosis therapy: Potentiator icenticaftor is superior to ivacaftor in improving function and maintaining stability of F508del CFTR. [PDF]

Sci Prog
Cholon DM, Aleksandrov LA, Quinney NL, Boyles SE, Jensen TJ, Aleksandrov AA, Gentzsch M.   +6 more
europepmc   +1 more source

Breaking boundaries or a small piece of the puzzle: can CFTR modulators transform bronchiectasis care? [PDF]

ERJ Open Res
Graeber SY, Frost F.
europepmc   +1 more source

Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation [PDF]

Esben Herborg Henriksen, Rikke Mulvad Sandvik, Mette Frahm Olsen, Tacjana Pressler, Thomas Bryrup, Christian Leo‐Hansen, Bibi Uhre Nielsen, Christine Højte, Marianne Skov, Frederik Buchvald, Inger Hee Mabuza Mathiesen, Tavs Qvist, Hanne Vebert Olesen, Sune Rubak, Camilla Bjørn Jensen, Daniel Faurholt‐Jepsen, Kim G. Nielsen   +16 more
openalex   +1 more source

The effect of modulators on lung function following inpatient treatment for CF exacerbations. [PDF]

Front Pediatr
Stone A, Haag MB, Muirhead CA, Markwardt S, MacDonald KD.   +4 more
europepmc   +1 more source

Transcriptomic Responses to Ivacaftor and Prediction of Ivacaftor Clinical Responsiveness

, 2019
Tao Sun, Zhe Sun, Yale Jiang, Annabel A. Ferguson, Joseph M. Pilewski, Jay K. Kolls, Wei Chen, Kong Chen   +7 more
openalex   +2 more sources

Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor. [PDF]

J Clin Transl Endocrinol
Burnet E, Grunewald D, Larger E, Camus-Bablon F, Eisenhauer C, Mifsud F, Martin C, Honoré I, Kanaan R, Carlier N, Fesenbeckh J, Mosnier-Pudar H, Burgel PR.   +12 more
europepmc   +1 more source

WS09.3 Increased maximal exercise capacity is associated with increased wellness across the spectrum of age and lung function in adults with cystic fibrosis (CF) after treatment with ivacaftor

, 2016
Brenda Button, Lisa M Wilson, D. Keating, J.W. Wilson   +3 more
openalex   +1 more source